US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds
Patent 11952349 was granted and assigned to Nuvation Bio on April, 2024 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
November 12, 2020
0
Date of Patent
April 9, 2024
0
Patent Applicant
Patent Application Number
17096743
0
Patent Citations
•••
Patent Inventor Names
Jayakanth Kankanala
0
Son Minh Pham
0
Christopher Paul Miller
0
Jeremy Pettigrew
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
